| Title | Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association |
| Authors | Wang, Ji-Guang Kario, Kazuomi Lau, Titus Wei, Yong Quek Park, Chang Gyu Kim, Cheol Ho Huang, Jun Zhang, Weizhong Li, Yong Yan, Peter Hu, Dayi |
| Affiliation | Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hypertens, Ctr Epidemiol Studies & Clin Trials,Ruijin Hosp, Shanghai 200025, Peoples R China. Jichi Med Univ, Sch Med, Dept Cardiovasc Med, Tochigi, Japan. Natl Univ Singapore Hosp, Dept Med, Singapore, Singapore. Tan Tock Seng Hosp, Dept Cardiol, Singapore, Singapore. Korea Univ, Sch Med, Guro Hosp, Dept Internal Med,Div Cardiol, Seoul, South Korea. Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Songnam, South Korea. Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Peoples R China. Fudan Univ, Shanghai Med Coll, Hushan Hosp, Dept Cardiol, Shanghai 200433, Peoples R China. Gleneagles Hosp, Singapore, Singapore. Mt Elizabeth Hosp, Singapore, Singapore. Beijing Univ, Renmin Hosp, Dept Cardiol, Beijing 100871, Peoples R China. Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hypertens, Ctr Epidemiol Studies & Clin Trials,Ruijin Hosp, Ruijin 2nd Rd 197, Shanghai 200025, Peoples R China. |
| Keywords | ambulatory blood pressure calcium channel blockers cardiovascular endpoints randomized controlled trials target organ damage CONVERTING ENZYME-INHIBITOR ISOLATED SYSTOLIC HYPERTENSION ANGIOTENSIN RECEPTOR BLOCKERS AMBULATORY BLOOD-PRESSURE LIPID-LOWERING TREATMENT MYOCARDIAL-INFARCTION RANDOMIZED-TRIAL CARDIOVASCULAR EVENTS NIFEDIPINE-RETARD CHINESE PATIENTS |
| Issue Date | 2011 |
| Publisher | hypertension research |
| Citation | HYPERTENSION RESEARCH.2011,34,(4),423-430. |
| Abstract | Dihydropyridine calcium channel blockers (CCBs) are widely prescribed for the management of hypertension in Eastern Asians. In this study, the Asian Pacific Heart Association's Writing Committee reviewed randomized controlled trials that were conducted in the Eastern Asian region and compared a CCB with an antihypertensive drug of another class. These trials studied ambulatory blood pressure, measures of target organ damage and cardiovascular events as outcomes. Eleven trials studied ambulatory blood pressure in hypertensive patients and demonstrated that the 24-h blood pressure reduction with CCBs was greater than with other classes of antihypertensive drugs, with a weighted mean difference of 5 mm Hg systolic and 3 mm Hg diastolic. Twelve trials that studied various measurements of target organ damage in hypertensive patients produced inconsistent results when comparing CCBs and other classes of antihypertensive drugs. Four trials that studied the hard outcomes had limited power, but confirmed the findings of previous placebo-controlled trials in the region and actively controlled trials in Europe and North America; they suggested that CCBs provided superior protection against stroke and that some agents, such as amlodipine, also provided similar protection against myocardial infarction. In conclusion, CCBs should be recommended as a preferred drug for the management of hypertension in the Eastern Asian region to improve blood pressure control and to confront the aggravating epidemic of stroke and coronary heart disease. Hypertension Research (2011) 34, 423-430; doi:10.1038/hr.2010.259; published online 13 January 2011 |
| URI | http://hdl.handle.net/20.500.11897/401282 |
| ISSN | 0916-9636 |
| DOI | 10.1038/hr.2010.259 |
| Indexed | SCI(E) |
| Appears in Collections: | 人民医院 |
